PDF(Pubmed)
Abstract：
Evidence from previous studies suggest that Lassa fever, a viral haemorrhagic fever endemic to West Africa has high case fatalities, particularly in pregnancy. While there have been remarkable innovations in vaccine development, with some Lassa vaccines undergoing early clinical trials. An understanding of Lassa antibody kinetics and immune responses will support vaccine design and development. However, there is currently no evidence on the antibody kinetics of Lassa (LASV) in pregnancy. Our study sought to estimate the efficiency of transplacental transfer of LASV IgG antibodies from the mother to the child.
The study made use of data from a prospective hospital-based cohort of pregnant women enrolled at the antenatal clinic and followed up at delivery between February and December 2019. Blood samples from mother-child pairs were evaluated for antibodies against Lassa virus. The study demonstrates a transplacental transfer of LASV IgG of 75.3% [60.0-94.0%], with a significant positive correlation between maternal and cord concentrations and a good level of agreement. The study also suggests that transfer may be more variable in women with \'de novo\' antibodies compared to those with pre-existing antibodies.
The study shows that maternal antibody levels play an important role in determining transfer efficiency of Lassa antibodies to the new-born; and while the evidence is preliminary, the study also suggests that transfer efficiency may be less stable in acute or recent infection, as such timing of vaccination before pregnancy, that is in women of childbearing age may be more appropriate for protection of both pregnant women and their neonates.
The study made use of data from a prospective hospital-based cohort of pregnant women enrolled at the antenatal clinic and followed up at delivery between February and December 2019. Blood samples from mother-child pairs were evaluated for antibodies against Lassa virus. The study demonstrates a transplacental transfer of LASV IgG of 75.3% [60.0-94.0%], with a significant positive correlation between maternal and cord concentrations and a good level of agreement. The study also suggests that transfer may be more variable in women with \'de novo\' antibodies compared to those with pre-existing antibodies.
The study shows that maternal antibody levels play an important role in determining transfer efficiency of Lassa antibodies to the new-born; and while the evidence is preliminary, the study also suggests that transfer efficiency may be less stable in acute or recent infection, as such timing of vaccination before pregnancy, that is in women of childbearing age may be more appropriate for protection of both pregnant women and their neonates.
摘要：
背景：先前研究的证据表明拉沙热，西非流行的病毒性出血热死亡率很高，特别是在怀孕期间。虽然在疫苗开发方面有显著的创新，一些拉萨疫苗正在进行早期临床试验。了解拉沙抗体动力学和免疫反应将支持疫苗设计和开发。然而,目前没有证据表明妊娠拉沙（LASV）的抗体动力学。我们的研究试图估计LASVIgG抗体从母亲到孩子的胎盘转移的效率。
结果：该研究利用了在2019年2月至12月期间在产前诊所登记并在分娩时随访的前瞻性医院孕妇队列的数据。评估了来自母子对的血液样品的抗拉沙病毒抗体。该研究表明LASVIgG的经胎盘转移为75.3％[60.0-94.0％]，母体和脐带浓度之间存在显着正相关，并且具有良好的一致性。该研究还表明，与具有预先存在的抗体的女性相比，具有“从头抗体”的女性的转移可能更加可变。
结论：该研究表明，母体抗体水平在确定拉沙抗体向新生儿的转移效率中起重要作用；虽然证据是初步的，该研究还表明，在急性或近期感染中，转移效率可能不太稳定，怀孕前接种疫苗的时间，也就是说，育龄妇女可能更适合保护孕妇及其新生儿。
结果：该研究利用了在2019年2月至12月期间在产前诊所登记并在分娩时随访的前瞻性医院孕妇队列的数据。评估了来自母子对的血液样品的抗拉沙病毒抗体。该研究表明LASVIgG的经胎盘转移为75.3％[60.0-94.0％]，母体和脐带浓度之间存在显着正相关，并且具有良好的一致性。该研究还表明，与具有预先存在的抗体的女性相比，具有“从头抗体”的女性的转移可能更加可变。
结论：该研究表明，母体抗体水平在确定拉沙抗体向新生儿的转移效率中起重要作用；虽然证据是初步的，该研究还表明，在急性或近期感染中，转移效率可能不太稳定，怀孕前接种疫苗的时间，也就是说，育龄妇女可能更适合保护孕妇及其新生儿。
